| dc.contributor.author | Igdem, Sefik | |
| dc.date.accessioned | 2019-08-13T12:10:23Z | |
| dc.date.accessioned | 2019-08-13T16:02:22Z | |
| dc.date.available | 2019-08-13T12:10:23Z | |
| dc.date.available | 2019-08-13T16:02:22Z | |
| dc.date.issued | 2015 | |
| dc.identifier.issn | 1309-9469 | |
| dc.identifier.uri | https://dx.doi.org/10.5472/mmj.11680 | |
| dc.identifier.uri | http://hdl.handle.net/11446/2786 | |
| dc.description | WOS: 000430063900005 | en_US |
| dc.description.abstract | Technological advances in radiation therapy delivery have permitted the use of high dose per fraction radiotherapy for early stage prostate cancer. Level I evidence supporting the safety and efficasy of hypofractionated radiotherapy is evolving. Moderate and extreme hypofractionation regimens show promising cancer control but long term results of noninferiority studies of both modalities are required before use in routine treatment as standard of care. | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | MARMARA UNIV, FAC MEDICINE | en_US |
| dc.identifier.doi | 10.5472/mmj.11680 | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Prostate cancer | en_US |
| dc.subject | Curative radiotherapy | en_US |
| dc.subject | Moderate and extreme hypo fractionation | en_US |
| dc.title | Treatment of prostate cancer by hypofractionated radiotherapy | en_US |
| dc.type | review | en_US |
| dc.relation.journal | MARMARA MEDICAL JOURNAL | en_US |
| dc.department | DBÜ | en_US |
| dc.identifier.issue | 4 | en_US |
| dc.identifier.volume | 28 | en_US |
| dc.identifier.startpage | 21 | en_US |
| dc.identifier.endpage | 23 | en_US |
| dc.relation.publicationcategory | Diğer | en_US |
| dc.department-temp | [Igdem, Sefik] Istanbul Bilim Univ, Med Sch, Dept Radiat Oncol, Istanbul, Turkey | en_US |
